Prediction of pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in humans using animal data

Xenobiotica

Volumn 37, Issue 1, 2007, Pages 91-102

  Shibayama, T ^a   Matsushita, Y ^a   Kurihara, A ^a   Hirota, T ^a   Ikeda, T ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Carbapenem antibiotic; CS 023; Interspecies scaling; Pharmacokinetics

Indexed keywords

CARBAPENEM DERIVATIVE; CS 023; HEPARIN; PLASMA PROTEIN; R 115685; RO 4908463; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISTRIBUTION VOLUME; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; INFUSION; KIDNEY TUBULE ABSORPTION; MALE; MATHEMATICAL MODEL; MONKEY; MOUSE; NONHUMAN; PLASMA CLEARANCE; RABBIT; STEADY STATE;

ANIMALS; BODY WEIGHT; CARBAPENEMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE;

ANIMALIA; CANIS FAMILIARIS; ORYCTOLAGUS CUNICULUS;

EID: 33845769429     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250601047889     Document Type: Article

References (25)

1. Adolph EF. 1949. Quantitative relations in the physiological constitutions of mammals. Science 109:579-585.
2. Boxenbaum H, Ronfeld R. 1983. Interspecies pharmacokinetic scaling and the Dedrick plots. American Journal of Physiology 245:R768-R775.
3. Chow HH. 1997. A physiologically based pharmacokinetic model of zidovudine (AZT) in the mouse: Model development and scale-up to humans. Journal of Pharmaceutical Sciences 86:1223-1228.
4. Craig WA. 1997. The pharmacology of meropenem, a new carbapenem antibiotic. Clinical Infectious Diseases 24(Suppl. 2):S266-S275.
5. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases 26:1-10.
6. Dedrick RL. 1973. Animal scale-up. Journal of Pharmacokinetics and Biopharmaceutics 1:435-461.
7. Drusano GL. 2003. Prevention of resistance: A goal for dose selection for antimicrobial agents. Clinical Infectious Diseases 36(Suppl. 1):S42-S50.
8. Efthymiopoulos C, Battaglia R, Benedetti MS. 1991. Animal pharmacokinetics and interspecies scaling of FCE 22101, a penem antibiotic. Journal of Antimicrobial Chemotherapy 27:517-526.
9. Kawai R, Mathew D, Tanaka C, Rowland M. 1998. Physiologically based pharmacokinetics of cyclosporine A: Extension to tissue distribution kinetics in rats and scale-up to human. Journal of Pharmacology and Experimental Therapeutics 287:457-468.
10. Kawamoto I, Shimoji Y, Kanno O, Kojima K, Ishikawa K, Matsuyama E, Ashida Y, Shibayama T, Fukuoka T, Ohya S. 2003. Synthesis and structure-activity relationships of novel parenteral carbapenems, CS-023 (R-115685) and related compounds containing an amidine moiety. Journal of Antibiotics 56:565-579.
11. Khor SP, Amyx H, Davis ST, Nelson D, Baccanari DP, Spector T. 1997. Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: Allometric scaling of animal data, pharmacokinetics and toxicokinetics of 5-fluorouracil in humans. Cancer Chemotherapy and Pharmacology 39:233-238.
12. Kim SH, Kim WB, Lee MG. 1998. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharmaceutics and Drug Disposition 19:231-235.
13. Koga T, Abe T, Inoue H, Takenouchi T, Kitayama A, Yoshida T, Masuda N, Sugihara C, Kakuta M, Nakagawa M, Shibayama T, Matsushita Y, Hirota T, Ohya S, Utsui Y, Fukuoka T, Kuwahara S. 2005. In vitro and in vivo antibacterial activities of CS-023 (RO4908463), a novel parenteral carbapenem. Antimicrobial Agents and Chemotherapy 49:3239-3250.
14. Kurihara A, Naganuma H, Hisaoka M, Tokiwa H, Kawahara Y. 1992. Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data. Antimicrobial Agents and Chemotherapy 36:1810-1816.
15. Matsushita H, Suzuki H, Sugiyama Y, Sawada Y, Iga T, Hanano M, Kawaguchi Y. 1990. Prediction of the pharmacokinetics of cefodizime and cefotetan in humans from pharmacokinetic parameters in animals. Journal of Pharmacobio-Dynamics 13:602-611.
16. Mehta SC, Lu DR. 1995. Interspecies pharmacokinetic scaling of BSH in mice, rats, rabbits, and humans. Biopharmaceutics and Drug Disposition 16:735-744.
17. Mitsuhashi Y, Sugiyama Y, Ozawa S, Nitanai T, Sasahara K, Nakamura K, Tanaka M, Nishimura T, Inaba M, Kobayashi T. 1990. Prediction of ACNU plasma concentration-time profiles in humans by animal scale-up. Cancer Chemotherapy and Pharmacology 27:20-26.
18. Pacifici GM, Viani A. 1992. Methods of determining plasma and tissue binding of drugs. Pharmacokinetics consequences. Clinical Pharmacokinetics 23:449-468.
19. Rennecke JT, Hirota T, Shibayama T, Matsushita Y, Kuwahara S, Puchler K, Ruhland A, Drewelow B. 2002. Safety, tolerability, and pharmacokinetics (PK) of CS-023, a new parenteral carbapenem, in healthy male volunteers. Paper presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2002, San Diego, CA, USA. Washington, DC: American Society for Microbiology. p. F-327.
20. Richter WF, Heizmann P, Meyer J, Starke V, Lave T. 1998. Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporins. Journal of Pharmaceutical Sciences 87:496-500.
21. Sawada Y, Hanano M, Sugiyama Y, Iga T. 1984. Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals. Journal of Pharmacokinetics and Biopharmaceutics 12:241-261.
22. Shibayama T, Matsushita Y, Kikuchi N, Kawai K, Hirota T, Kuwahara S. 2000. R-115685, a novel parenteral Carbapenem: Pharmacokinetics and metabolism in laboratory animals. Paper presented at the 40th Interscience Conference on Antibacterial Agents and Chemotherapy, 17-20 September 2000, Toronto, Ont., Canada. Washington, DC: American Society for Microbiology. p. F-1233.
23. Takahagi H, Hirota H, Matsushita Y, Muramatsu M, Tanaka M, Matsuo E. 1991. In vitro dehydropeptidase-I activity and its hydrolytic activity of panipenem in several tissues in animal species and their influence on the disposition of panipenem in vivo. Chemotherapy (Tokyo) 39(Suppl. 3):236-241.
24. Thomson KS, Moland ES. 2004. CS-023 (R-115685), a novel carbapenem with enhanced in vitro activity against oxacillin-resistant staphylococci and Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 54:557-562.
25. Tsuji A, Sato H, Tamai I, Adachi H, Nishihara T, Ishiguro M, Ohnuma N, Noguchi T. 1990. Physiologically based pharmacokinetics of a new penem, SUN5555, for evaluation of in vivo efficacy. Drug Metabolism and Disposition 18:245-252.